New Obesity Target Screening Service
InquiryThe global rise in metabolic health challenges has underscored the urgent need for a shift from broad-spectrum interventions to highly specific, mechanism-based therapeutic strategies. At Protheragen, we recognize that the next generation of anti-obesity treatments requires deep insight into the complex molecular interactions governing energy homeostasis, lipid metabolism, and gut-brain signaling.
Advanced Preclinical Obesity Target Discovery
Our new obesity target screening service is designed specifically for preclinical research, providing biotech and pharmaceutical partners with a robust, unbiased, and high-throughput platform to identify and validate novel therapeutic targets. By moving beyond traditional single-pathway approaches, we enable the discovery of innovative, durable targets that can address the biological complexity of metabolic dysregulation. Whether you are investigating novel GPCRs, metabolic enzymes, or complex protein-protein interaction networks, our integrated, data-driven approach ensures your pipeline progresses with higher precision and scientific confidence.
Core Technologies
Protheragen leverages a suite of cutting-edge biophysical and chemical biology techniques designed to capture drug-target interactions in their near-native states:
We utilize advanced methods like drug affinity responsive target stability to detect binding events without the need for chemical modification, ensuring that we measure authentic biological interactions.
Our activity-based protein profiling (ABPP) and proximity labeling technologies allow us to map the functional state of the proteome within complex cellular environments.
We employ specialized microarray systems to rapidly screen for interactions across broad panels of membrane proteins and potential metabolic targets.
Solution Scope
Protheragen offers a comprehensive portfolio of services to support every stage of obesity target discovery:
Utilizing advanced modeling to understand target architecture.
Identifying binding partners in native lysates via protease susceptibility.
Directly monitoring the functional activity of target enzymes.
Custom engineering of probes to optimize screening precision.
Measuring ligand-induced stabilization in living cells.
Focused interrogation of G-protein coupled receptors.
Classical isolation of binding complexes for further analysis.
Capturing elusive interaction networks in the membrane environment.
Broad, high-throughput identification of therapeutic candidates.
Detailed characterization of target binding sites.
Providing high-quality protein for downstream assays.
Confirming pharmacological relevance in disease-relevant models.
Workflow
Our systematic approach is built on proven preclinical research frameworks to ensure reliability and speed:
Fields of Application
Our services are essential for research programs focused on:
- Metabolic Syndrome & Insulin Resistance: Identifying targets that restore metabolic flexibility.
- Lipid Metabolism Modulation: Targeting enzymes involved in lipid absorption and energy storage.
- Appetite & Satiety Regulation: Exploring novel neuroendocrine targets beyond current standard-of-care agents.
- Adipose Tissue Remodeling: Screening for proteins that influence thermogenesis and healthy fat distribution.
Advantages
Protheragen provides a competitive edge through technical expertise and commitment to scientific rigor:
Unbiased Discovery
Our platform identifies targets based on actual physical interaction, not just theoretical pathway involvement.
Near-Native Physiological Conditions
By prioritizing label-free, cell-based assays like CETSA, we reduce artifacts associated with chemical tagging.
Integration with Advanced Data Analytics
We combine our experimental data with predictive models to prioritize targets with the highest potential for clinical translation.
Supporting Evidence
Our methods are supported by extensive data regarding the success of biophysical screens in uncovering novel metabolic drivers.
Customer Review
Identifying Novel Targets Through Precision Biophysical Screening
"Working with Protheragen has been a transformative experience for our internal pipeline. Their team didn't just provide a service; they acted as an extension of our own R&D department. The sensitivity of their DARTS-based screening allowed us to identify a novel target we had previously missed using standard methods. Their deep technical expertise in metabolic pathways gave us confidence in our next steps."
Dr. S. J., Director of Preclinical Development
Accelerating Discovery with Integrated and Data-Driven Validation
"The transition from target identification to validation was seamless. Protheragen's ability to combine high-end biophysical assays like CETSA with practical, disease-relevant models is exactly what we needed. We are already planning our next project with them to further explore our target's role in adipose tissue signaling."
Dr. M. T., Senior Research Scientist
Frequently Asked Questions
-
Do you offer clinical services?
Protheragen is strictly a preclinical research partner. We do not provide clinical services, but we provide the high-quality data necessary to advance your programs into clinical development.
-
How do you handle membrane proteins, which are notoriously difficult?
We utilize specialized GPCR-specific microarrays and proximity labeling designed to maintain the conformational integrity of membrane proteins in their native environment.
-
What is the advantage of DARTS over traditional screening?
DARTS is label-free, meaning we don't need to modify your test compounds. This maintains their biological activity and ensures we measure true, native drug-target interactions.
-
Can your screening identify targets for specific obesity phenotypes?
Yes. We work with you to select cellular models that reflect the specific metabolic phenotype—such as insulin-resistant or thermogenic-deficient—you wish to address.
-
How quickly can we expect results?
Timelines vary by project scope, but our automated, high-throughput platforms are designed to significantly compress the traditional target-identification timeline.
-
Do you provide support after the screening is complete?
Absolutely. Our team offers ongoing consultation and additional validation services to ensure you have a clear path to drug optimization.
-
Is your data suitable for regulatory filings?
We adhere to high data-quality standards, providing the rigorous preclinical evidence base that is essential for IND-enabling studies.
-
What if our target is a protein-protein interaction?
Our proximity labeling and pull-down services are highly effective at mapping complex interaction networks beyond simple small-molecule binding.
-
How do I know if your service is right for my project?
We encourage a preliminary technical discussion. Please reach out to us, and we will assess your project goals to ensure our platform is a perfect fit.
Contact Us
At Protheragen, we are dedicated to providing the precision, speed, and insight required to fuel your obesity drug discovery pipeline. Welcome to Contact Protheragen. Our expert team is ready to help you navigate the complexities of metabolic research.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.